Gilead Sciences $GILD
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS58
PHASE 3 / 2-327
RECRUITING16
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO54%
Delay Index: of 46 active trials registered more than a year ago, 25 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.7 months). See all sponsors →
Open Gilead Sciences on the live radar map → 📅 $GILD readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tenofovir DF NCT01651403 |
P3 | Active, not recruiting | Chronic Hepatitis B | 90 | 2017-08-07 (+25 mo) |
| CAPELLA NCT04150068 |
P2/3 | Active, not recruiting | HIV-1-infection | 72 | 2020-10-05 (-7 mo) |
| Sacituzumab Govitecan-hziy NCT04454437 |
P2 | Active, not recruiting | Metastatic Triple-negative Breast Cancer | 80 | 2021-08-06 (-3 mo) |
| EVOKE-01 NCT05089734 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 603 | 2023-11-29 (-5 mo) |
| ISL NCT05052996 |
P2 | Active, not recruiting | HIV-1 Infection | 142 | 2023-12-19 (+17 mo) |
| PURPOSE 1 NCT04994509 |
P3 | Active, not recruiting | Pre-Exposure Prophylaxis of HIV Infection | 5368 | 2024-05-27 (+3 mo) |
| Teropavimab NCT05729568 |
P2 | Active, not recruiting | HIV-1 Infection | 83 | 2024-07-02 (-9 mo) |
| PURPOSE 2 NCT04925752 |
P3 | Active, not recruiting | Pre-Exposure Prophylaxis of HIV Infection | 3292 | 2024-08-21 (+8 mo) |
| TROPiCS-03 NCT03964727 |
P2 | Active, not recruiting | Metastatic Solid Tumor | 227 | 2025-01-15 (+34 mo) |
| B/F/TAF (Adult Strength) NCT02881320 |
P2/3 | Active, not recruiting | HIV-1 Infection | 177 | 2025-03-24 (+94 mo) |
| ATV NCT02016924 |
P2/3 | Active, not recruiting | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections | 133 | 2025-06-13 (+94 mo) |
| ARTISTRY-1 NCT05502341 |
P2/3 | Active, not recruiting | HIV-1-infection | 689 | 2025-09-29 (-3 mo) |
| ARTISTRY-2 NCT06333808 |
P3 | Active, not recruiting | HIV-1-infection | 577 | 2025-10-27 (-1 mo) |
| SWIFT NCT06290934 |
P2 | Active, not recruiting | Ulcerative Colitis | 228 | 2026-03-04 (-14 mo) |
| ISLEND-1 NCT06630286 |
P3 | Active, not recruiting | HIV-1-infection | 609 | 2026-04-17 (-1 mo) |
| ISLEND-2 NCT06630299 |
P3 | Active, not recruiting | HIV-1-Infection | 600 | 2026-04-23 (-13 mo) |
| PURPOSE 5 NCT06513312 |
P2 | Active, not recruiting | Pre-Exposure Prophylaxis of HIV Infection | 268 | 2026-05-28 (-7 mo) |
| PURPOSE 3 NCT06101329 |
P2 | Active, not recruiting | Pre-Exposure Prophylaxis of HIV Infection | 253 | 2026-07-22 (-11 mo) |
| PURPOSE 4 NCT06101342 |
P2 | Active, not recruiting | Pre-Exposure Prophylaxis of HIV Infection | 181 | 2026-07-27 (-11 mo) |
| Sacituzumab Govitecan-hziy NCT05119907 |
P2 | Active, not recruiting | Solid Tumor | 53 | 2026-10 (+47 mo) |
| TAF NCT02932150 |
P2 | Active, not recruiting | Chronic Hepatitis B | 150 | 2026-10-27 (+89 mo) |
| Sacituzumab Govitecan-hziy NCT04639986 |
P3 | Active, not recruiting | Metastatic Breast Cancer | 331 | 2026-12 (+48 mo) |
| PALEKONA NCT06029972 |
P2 | Active, not recruiting | Ulcerative Colitis | 176 | 2027-01 (+19 mo) |
| ASCENT-04 NCT05382286 |
P3 | Active, not recruiting | Triple Negative Breast Cancer; PD-L1 Positive | 443 | 2027-02 |
| EVOKE-02 NCT05186974 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 193 | 2027-03 (+46 mo) |
| Oral Lenacapavir NCT06749054 |
P2 | Recruiting | HIV-1-infection | 12 | 2027-03 (+12 mo) |
| VELOCITY-HNSCC NCT06727565 |
P2 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 39 | 2027-03 (+7 mo) |
| ASCENT-J02 NCT05101096 |
P1/2 | Active, not recruiting | Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer | 135 | 2027-05 (+50 mo) |
| Sacituzumab govitecan-hziy (SG) NCT05633654 |
P3 | Recruiting | Triple Negative Breast Cancer | 1514 | 2027-06 |
| B/F/TAF NCT07841990 |
P2 | Recruiting | HIV-1 Infection | 125 | 2027-08 |
| GS-3242 Tablet NCT07645287 |
P2 | Recruiting | HIV-1-infection | 175 | 2027-08 |
| GS-1179 NCT07912996 |
P2 | Not yet recruiting | HSV-2 Infection | 300 | 2027-11 |
| NAPISTAR1-01 NCT06303505 |
P1/2 | Recruiting | Ovarian Cancer; Non-small Cell Lung Cancer | 334 | 2027-12 (+11 mo) |
| EDGE-Lung NCT05676931 |
P2 | Active, not recruiting | Advanced Non-Small Cell Lung Cancer | 400 | 2027-12 (+15 mo) |
| WONDERS1 NCT06544733 |
P2/3 | Active, not recruiting | HIV-1-Infection | 675 | 2028-01 |
| OC NCT07736937 |
P1/2 | Recruiting | Ovarian Cancer | 72 | 2028-03 |
| ASCENT-07 NCT05840211 |
P3 | Active, not recruiting | Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer | 654 | 2028-04 (+31 mo) |
| Sacituzumab Govitecan-hziy (SG) NCT06926920 |
P1/2 | Recruiting | Triple Negative Breast Cancer | 100 | 2028-06 |
| STAR-121 NCT05502237 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 1021 | 2028-06 (+6 mo) |
| ASCENT-03 NCT05382299 |
P3 | Active, not recruiting | Triple Negative Breast Cancer; PD-L1 Negative | 623 | 2028-07 (+14 mo) |
| PURPOSE 365 NCT07047716 |
P3 | Active, not recruiting | HIV Pre-exposure Prophylaxis | 339 | 2028-09 |
| Seladelpar 5 mg Capsule NCT03301506 |
P3 | Active, not recruiting | Primary Biliary Cirrhosis | 340 | 2028-11 (+95 mo) |
| Denikitug NCT07527858 |
P2 | Recruiting | Advanced Microsatellite Stable Colorectal Cancer | 170 | 2028-12 |
| Seladelpar NCT07841977 |
P2 | Recruiting | Primary Biliary Cholangitis | 132 | 2028-12 |
| TUB-030 NCT06657222 |
P1/2 | Recruiting | Advanced Solid Tumors; HNSCC | 250 | 2028-12 |
| Lenacapavir NCT07682961 |
P3 | Recruiting | HIV Infections | 590 | 2029-03 |
| Lenacapavir NCT07683000 |
P3 | Recruiting | HIV-1-infection | 590 | 2029-03 |
| TUB-040 NCT07806773 |
P2 | Not yet recruiting | NSCLC; Non Small Cell Lung Cancer | 80 | 2029-05 |
| ASCENT-GYN-01 NCT06486441 |
P3 | Active, not recruiting | Endometrial Cancer | 640 | 2029-06 |
| VELOCITY-Lung NCT05633667 |
P2 | Active, not recruiting | Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer | 192 | 2029-09 (+32 mo) |
| NAPISTAR 1-03 NCT07743541 |
P1/2 | Not yet recruiting | Uterine Endometrial Cancer | 100 | 2029-09 |
| EVOKE-SCLC-04 NCT06801834 |
P3 | Recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 695 | 2029-10 |
| Denikitug NCT07546812 |
P2 | Active, not recruiting | HER2-negative; Gastroesophageal Junction | 120 | 2030-01 |
| GS-4321 NCT07096193 |
P1/2 | Recruiting | Chronic Hepatitis Delta | 200 | 2030-01 (+41 mo) |
| TROPHY U-01 NCT03547973 |
P2 | Active, not recruiting | Metastatic Urothelial Cancer | 502 | 2030-04 (+119 mo) |
| Lenacapavir NCT06532656 |
P2/3 | Active, not recruiting | HIV-1-infection | 75 | 2030-07 (+29 mo) |
| AFFIRM NCT06051617 |
P3 | Recruiting | Primary Biliary Cholangitis | 402 | 2030-08 (+13 mo) |
| GS-3242 Tablet NCT07708727 |
P2/3 | Recruiting | HIV-1-infection | 700 | 2030-10 |